FIELD: medicine; oncology.
SUBSTANCE: invention can be used to predict the status of the HER2/neu receptor in metastatic axillary lymph nodes in patients with breast cancer. At the stage of clinical examination, prior to the start of systemic treatment, patients with breast cancer with metastases in the axillary lymph nodes are administered the radionuclide pharmaceutical preparation [99mTc]Tc-ADAPT6 at a dose of 500 μg. After 2 hours, single-photon emission computed tomography (SPECT/CT) of the chest organs is performed and the accumulation of radiopharmaceuticals in the metastatic axillary lymph node X is assessed. The value of the regression equation Y is calculated using the formula Y = -6.827 + 1.751*X, where -6.827 is the value of the regression coefficient of the free term; X is an indicator of the quantitative accumulation of radiopharmaceuticals in the metastatic axillary lymph node; 1.751 is the value of the regression coefficient of this feature. The probability P of assessing the status of the HER2/neu receptor in the metastatic axillary lymph node is determined by the formula P = eY/(1 + eY). At P≥ 50% high probability of HER2-positive tissue status of the primary tumor node is predicted, and at P<50% low probability of HER2-positive tissue status of the primary tumor node is predicted.
EFFECT: method provides improved accuracy of HER2/neu receptor status prediction in metastatic axillary lymph nodes in patients with breast cancer.
1 cl, 2 dwg, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREDICTING STATUS OF EPIDERMAL GROWTH FACTOR HER2/NEU IN METASTATIC LYMPH NODES IN BREAST CANCER PATIENTS | 2021 |
|
RU2757960C1 |
METHOD FOR PREDICTING THE STATUS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR HER2/NEU IN THE MAIN TUMOR NODE IN BREAST CANCER PATIENTS | 2021 |
|
RU2762317C1 |
METHOD FOR PREDICTION OF EPIDERMAL GROWTH FACTOR RECEPTOR STATUS HER2/NEU IN PRIMARY TUMOUR IN PATIENTS WITH BREAST CANCER | 2021 |
|
RU2766248C1 |
METHOD FOR PREDICTION OF HER2/NEU EPIDERMAL GROWTH FACTOR RECEPTOR STATUS IN MAIN TUMOR NODE IN BREAST CANCER PATIENTS | 2022 |
|
RU2779751C1 |
METHOD OF BREAST CANCER DIAGNOSTICS WITH HER2/NEU HYPEREXPRESSION | 2022 |
|
RU2800818C1 |
METHOD OF DIAGNOSTICS OF REMOTE METASTASIS IN BREAST CANCER PATIENTS WITH HER2/NEU HYPEREXPRESSION | 2022 |
|
RU2800864C1 |
METHOD FOR EVALUATING NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS WITH HER2/NEU OVEREXPRESSION | 2022 |
|
RU2785387C1 |
RADIONUCLIDE DIAGNOSTIC TECHNIQUE FOR BREAST CANCER WITH Her2/neu HYPEREXPRESSION | 2019 |
|
RU2720801C1 |
DIAGNOSTIC TECHNIQUE FOR STOMACH CANCER WITH HER2/NEU OVEREXPRESSION | 2020 |
|
RU2739107C1 |
METHOD FOR RADIONUCLIDE DIAGNOSING OPERABLE BREAST CANCER WITH OVEREXPRESSION OF HER2/NEU | 2019 |
|
RU2702294C1 |
Authors
Dates
2023-09-21—Published
2023-06-06—Filed